Recent advances in triple negative breast cancer: the immunotherapy era

Abstract Background Several accomplishments have been achieved in triple-negative breast cancer (TNBC) research over the last year. The phase III IMpassion130 trial comparing chemotherapy plus atezolizumab versus chemotherapy plus placebo brought breast cancer into the immunotherapy era. Nevertheles...

Full description

Bibliographic Details
Published in:BMC Medicine
Main Authors: Antonio Marra, Giulia Viale, Giuseppe Curigliano
Format: Article
Language:English
Published: BMC 2019-05-01
Subjects:
Triple-negative breast cancer
Immunotherapy
PD-L1
Biomarkers
Checkpoint inhibitors
Online Access:http://link.springer.com/article/10.1186/s12916-019-1326-5

Internet

http://link.springer.com/article/10.1186/s12916-019-1326-5

Similar Items